Dr Reddys Laboratories (RDY) Capital Expenditures (2009 - 2026)

Dr Reddys Laboratories has reported Capital Expenditures for 17 years, with the latest figure at -$36.2 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 54.86% year-over-year to -$36.2 million in Q2 2026; TTM through Jun 2026 was -$266.2 million, a 9.61% increase from a year earlier, with the FY2026 full-year figure at -$249.0 million, up 22.67% from the prior year.
• Capital Expenditures was -$36.2 million for Q2 2026 at Dr Reddys Laboratories, up from -$59.9 million in the prior quarter.
• The five-year high for Capital Expenditures was -$31.4 million in Q1 2023, with the low at -$90.0 million in Q3 2024.
• Average Capital Expenditures over 5 years is -$51.2 million, with a median of -$45.3 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Capital Expenditures slumped 101.9% in 2024, then soared 54.86% in 2026.
• Over 5 years, Capital Expenditures stood at -$35.6 million in 2022, then dropped by 29.31% to -$46.1 million in 2023, then sank by 95.3% to -$90.0 million in 2024, then jumped by 33.42% to -$59.9 million in 2025, then soared by 39.59% to -$36.2 million in 2026.
• The last three Capital Expenditures figures came in at -$36.2 million (Q2 2026), -$59.9 million (Q3 2025), and -$80.2 million (Q2 2025), per Business Quant data.